Cellectar Biosciences, Inc.
$2.95
▲
2%
2026-04-21 06:05:00
www.cellectar.com
NCM: CLRB
Explore Cellectar Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$12.21 M
Current Price
$2.95
52W High / Low
$20.7 / $2.43
Stock P/E
—
Book Value
$1.89
Dividend Yield
—
ROCE
-224.66%
ROE
-1.7%
Face Value
—
EPS
$-8.35
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
11
Beta
0.4
Debt / Equity
4.13
Current Ratio
2.96
Quick Ratio
2.96
Forward P/E
-0.89
Price / Sales
—
Enterprise Value
$0.82 M
EV / EBITDA
-0.04
EV / Revenue
—
Rating
None
Target Price
$33.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 2. | Liminatus Pharma, Inc. | $0.22 | — | $9.83 M | — | 30.51% | — | $33.66 / $0.16 | $-0.06 |
| 3. | Filana Therapeutics, Inc. | $1.75 | — | $84.54 M | — | -128.99% | -82.66% | $2.27 / $1.53 | $1.54 |
| 4. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 5. | 60 Degrees Pharmaceuticals, Inc. | $1.84 | — | $4.69 M | — | -220.2% | -2.01% | $17.68 / $1.29 | $-5.25 |
| 6. | Cingulate Inc. | $6.03 | — | $66.77 M | — | -418.81% | -4.51% | $11.89 / $3.2 | $0.35 |
| 7. | Forte Biosciences, Inc. | $34.43 | — | $674.68 M | — | -113.91% | -1.22% | $35.8 / $4.9 | $4.71 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -5.69 M | -4.85 M | -6.04 M | -6.4 M | -12.74 M | — |
| Net Profit | -5.3 M | -4.44 M | -5.45 M | -6.6 M | -2.36 M | — |
| EPS in Rs | -1.25 | -1.05 | -1.28 | -1.56 | -0.56 | -12.13 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -22.98 M | -51.78 M | -38.96 M | -28.81 M |
| Net Profit | -21.79 M | -44.58 M | -42.77 M | -31.79 M |
| EPS in Rs | -5.14 | -10.51 | -10.09 | -7.5 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 14.98 M | 25.47 M | 12.08 M | 21.59 M |
| Total Liabilities | 6.44 M | 11.18 M | 27.23 M | 13.44 M |
| Equity | 8.54 M | 14.29 M | -15.16 M | 8.15 M |
| Current Assets | 14.04 M | 24.25 M | 10.45 M | 20.53 M |
| Current Liabilities | 4.75 M | 9.39 M | 25.36 M | 11.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.12 M | -47.58 M | -32.38 M | -25.22 M |
| Investing CF | -0.01 M | -0.1 M | -0.86 M | -0.23 M |
| Financing CF | 13.03 M | 61.41 M | 22.94 M | 9.61 M |
| Free CF | -23.12 M | -47.69 M | -33.24 M | -25.45 M |
| Capex | -0.01 M | -0.1 M | -0.86 M | -0.23 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -4.23% | -34.53% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-24 | 1:0.0333333 |
| 2022-07-22 | 1:0.1 |